Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
313.89
+8.18 (2.68%)
May 11, 2026, 9:38 AM EDT - Market open
Krystal Biotech Stock Forecast
Stock Price Forecast
The 11 analysts that cover Krystal Biotech stock have a consensus rating of "Strong Buy" and an average price target of $298.45, which forecasts a -4.92% decrease in the stock price over the next year. The lowest target is $176 and the highest is $378.
Price Target: $298.45 (-4.92%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Krystal Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 8 | 9 | 9 | 9 | 9 |
| Buy | 1 | 1 | 0 | 0 | 0 | 1 |
| Hold | 2 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 11 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $371 → $378 | Strong Buy | Maintains | $371 → $378 | +20.42% | May 5, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $295 → $300 | Buy | Maintains | $295 → $300 | -4.43% | May 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $310 | Strong Buy | Reiterates | $310 | -1.24% | May 4, 2026 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Mar 27, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $224 → $284 | Strong Buy | Maintains | $224 → $284 | -9.52% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
539.10M
from 389.13M
Increased by 38.54%
Revenue Next Year
710.96M
from 539.10M
Increased by 31.88%
EPS This Year
7.86
from 6.84
Increased by 14.94%
EPS Next Year
10.57
from 7.86
Increased by 34.49%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 631.9M | 926.1M | ||||||
| Avg | 539.1M | 711.0M | ||||||
| Low | 439.9M | 608.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 62.4% | 71.8% | ||||||
| Avg | 38.5% | 31.9% | ||||||
| Low | 13.1% | 12.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 10.07 | 18.09 | |||||
| Avg | 7.86 | 10.57 | |||||
| Low | 5.66 | 6.39 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 47.2% | 130.1% | |||||
| Avg | 14.9% | 34.5% | |||||
| Low | -17.2% | -18.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.